Component 1 (Overview): The MTN Leadership Group comprises a Leadership Operations Center (LOC), Laboratory Center (LC), and Statistical and Data Management Center (SDMC), for each of which thematically linked but separate applications have been submitted. The LOC is led by two Principal Investigators: Drs. Sharon Hillier and Ian McGowan, both located at the Magee Womens Research Institute in Pittsburgh, each providing distinct but complementary expertise. Dr. Hillier provides primary leadership for MTN's vaginal microbicide development and female reproductive health; Dr. McGowan leads the MTN rectal microbicide research agenda and mucosal immunology program. The LOC also comprises the PIs for the Operations Support Core (Cates), University of Washington Core (Celum), the LC (Dezzutti), and the SDMC (Brown), which work together and with the network-affiliated Clinical Trial Units/Sites to implement the research agenda. The LOC is supported by 3 Working Groups--Biomedical Science, Behavioral Research, and Community--and 3 Network Committees: Study Monitoring, Network Evaluation, and Manuscript Development. The PIs and the Chairs of the Working Groups and Network Committees constitute the MTN Executive Committee, the primary decision-making body for MTN activity. Established in 2006 with NIH funding, the MTN was charged with developing safe and effective microbicides from the early stages of product development through final approval by regulatory authorities. The present grant application details MTN contributions to HIV prevention, defines network leadership and operational structures for the next funding cycle--a 7-year period from 12/1/13 through 11/30/20-and describes 6 specific areas of challenge and needed improvement. The application presents 15 Specific Aims for MTN that build on its 6 years of experience with developing and/or completing 33 clinical protocols, associated lessons learned, obstacles encountered, gaps identified; and environmental changes and pressures.

Public Health Relevance

Microbicides are new drug products which are being developed for use by people for prevention of HIV infection. This grant application describes a leadership structure for the Microbicide Trials Network, a clinical trials network whose purpose is to develop microbicide products from the early stages of product development through final approval by regulatory authorities.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Black, Roberta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Magee-Women's Research Institute and Foundation
United States
Zip Code
Giguere, Rebecca; Brown III, William; Balán, Ivan C et al. (2018) Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial? J Am Med Inform Assoc 25:393-400
Giguere, Rebecca; Rael, Christine Tagliaferri; Sheinfil, Alan et al. (2018) Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav 22:388-401
Brown 3rd, William; Giguere, Rebecca; Sheinfil, Alan et al. (2018) Challenges and solutions implementing an SMS text message-based survey CASI and adherence reminders in an international biomedical HIV PrEP study (MTN 017). J Biomed Inform 80:78-86
Abbai, Nathlee S; Nyirenda, Makandwe; Naidoo, Sarita et al. (2018) Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa. AIDS Behav 22:2172-2180
Laborde, Nicole D; Pleasants, Elizabeth; Reddy, Krishnaveni et al. (2018) Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex. AIDS Behav 22:437-446
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411
Justman, Jessica E; Nair, Gonasagrie Lulu; Hendrix, Craig W et al. (2018) Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. J Acquir Immune Defic Syndr 78:175-182
Mhlanga, Felix G; Noguchi, Lisa; Balkus, Jennifer E et al. (2018) Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. HIV Clin Trials 19:8-14
Balkus, Jennifer E; Brown, Elizabeth R; Palanee-Phillips, Thesla et al. (2018) Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. J Acquir Immune Defic Syndr 77:e8-e10
Musara, Petina; Montgomery, Elizabeth T; Mgodi, Nyaradzo M et al. (2018) How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe. AIDS Behav 22:877-886

Showing the most recent 10 out of 113 publications